At Alpha Clinical Development, we believe that science is driven by collaboration, scientific knowledge exchange, and a shared commitment to improving patient outcomes. We recognize that global scientific conferences are more than annual milestones in the medical calendar. They are important forums where new ideas emerge, regulatory priorities are discussed, and the future of clinical development and pharmacovigilance is shaped. Our involvement in recent events such as the ERS, WDS and UEG offered not only a window into the latest advances in medicine but also an important reminder of the responsibilities we share as a clinical research partner.
Spotlight on the Conferences
Insights from the European Respiratory Society (ERS)
The ERS Congress 2025 is centered on the theme “Respiratory Health Around the Globe”, reflecting the universal challenge of lung disease across populations. The congress emphasizes the global burden of respiratory disease, highlights both the differences and similarities in challenges across regions and calls for collective solutions to improve outcomes worldwide. This year, the spotlight was on novel biologics, and their
combinations, rare pulmonary conditions, and the integration of digital technologies such as connected inhalers and drug delivery. These innovations represent significant progress for patients but also bring complexity to clinical trial design and execution.
For Alpha Clinical Development, these priorities align strongly with our role as a global CRO partner. Respiratory trials demand careful study design, particularly where patient populations are vulnerable, treatment compliances and endpoints complex. Our expertise in clinical operations and pharmacovigilance ensures that studies not only meet regulatory and scientific expectations but also showcasing the broader aim of improving respiratory health across diverse settings. By aligning with ERS’s vision, we help sponsors deliver trials that are robust, inclusive for diversified population and capable of informing solutions that benefit patients or otherwise.
Patient Safety at the Heart: Reflections from WDS
The World Drug Safety Congress continues to be a defining event for pharmacovigilance and risk management. In 2025, discussions focused on the application of AI in signal detection, the harmonization of global safety regulations, and the integration of real-world evidenceinto safety monitoring. These themes highlight the dual challenge of managing increasingly complex safety data while ensuring patient protection remains as the top priority.
At Alpha Clinical Development, pharmacovigilance lies at the heart of our services. Beyond compliance, we see safety oversight as a responsibility to patients and the healthcare systems that serve them. Our solutions, ranging from case processing and expedited reporting to aggregate submissions and lifecycle risk management, are designed to anticipate challenges, enhance transparency, and strengthen trust between science and society.
Advancing Gastroenterology at UEG week
Gastroenterology continues to evolve at remarkable speed, and two major meetings, UEG Week – offered complementary perspectives on the future of digestive health.
This year at UEGW discussions covered inflammatory bowel disease, hepatology, GI cancers, and the growing role of precision medicine. These therapeutic frontiers require clinical trial approaches that are adaptive, patient-focused, and capable of integrating both established and novel endpoints.
UEG Week, meanwhile, highlighted the importance of education and multidisciplinary collaboration. It’s Postgraduate Teaching Programme(PGT), a dynamic two-day experience built around interactive case discussions, debates, and faculty engagement, provided clinicians and researchers with practical, evidence-based updates for day-to-day practice. The restructured three-year curriculum, now in its second year, incorporates the most recent advancements in gastroenterology and hepatology.
In addition to teaching, UEG Week’s diverse formats, live endoscopy, abstract sessions, late- breaking data, and moderated posters, ensured that both basic science and clinical practice were represented, from mechanistic insights to hands-on procedural expertise. Overall, UEG Week show the dual priorities of the field: advancing therapies through cutting-edge research while ensuring that knowledge is effectively translated into clinical care.
Alpha Clinical Development brings therapeutic expertise and operational precision to gastroenterology research. We understand the complexities of these conditions, and these themes highlight the essential role of a trusted CRO partner in supporting sponsors through this complex and fast-moving landscape. From clinical trial design and operational execution to pharmacovigilance, regulatory compliance and generating meaningful data.
Our services ensure that innovations in gastroenterology are developed with scientific accuracy, patient safety, and global relevance at the forefront. By aligning with the priorities emphasized at both UEG Week, we help translate breakthrough science into real-world solutions for patients worldwide.
Bridging Innovation and Responsibility – A Shared Mission for the Future
Taken together, ERS and WDS, illustrate the shared imperative facing modern healthcare: to advance science at speed while upholding the highest standards of safety. At Alpha Clinical Development, our mission is to bridge this imperative, supporting sponsors with full-service solutions that integrate clinical operations, regulatory insight, and pharmacovigilance expertise.
As global congresses continue to highlight the evolving challenges and opportunities of medicine, we remain committed to translating these insights into practical solutions, that advance research, and safeguard patients, and bring innovation to life.
Sophia Nematollahi 
